Targeted disruption of carcinoembryonic antigen-related cell adhesion molecule 1 promotes diet-induced hepatic steatosis and insulin resistance

Endocrinology

Volumn 150, Issue 8, 2009, Pages 3503-3512

  Xu, Elaine ^a   Dubois, Marie Julie ^a   Leung, Nelly ^b,c   Charbonneau, Alexandre ^a   Turbide, Claire ^b   Avramoglu, Rita Kohen ^a   DeMarte, Luisa ^b   Elchebly, Mounib ^d   Streichert, Thomas ^e   Lévy, Emile ^d   Beauchemin, Nicole ^b,c   Marette, André ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF MONTREAL   (Canada)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CHOLESTEROL ESTER; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOX01; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; FATTY LIVER; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; HISTOPATHOLOGY; INSULIN CLEARANCE; INSULIN METABOLISM; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIVER DYSFUNCTION; LIVER INJURY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BLOTTING, WESTERN; CELL ADHESION MOLECULES; CHOLESTEROL; DIETARY FATS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; IMMUNOPRECIPITATION; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; LIPOPROTEINS, HDL; LIVER; MALE; MICE; MICE, MUTANT STRAINS; SIGNAL TRANSDUCTION; TRIGLYCERIDES;

EID: 67651162136     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2008-1439     Document Type: Article

References (56)

1. Liou I, Kowdley KV 2006 Natural history of nonalcoholic steatohepatitis. J Clin Gastroenterol 40:S11-S16
2. Fan JG 2008 Impact of non-alcoholic fatty liver disease on accelerated metabolic complications. J Dig Dis 9:63-67
3. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S 2008 Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 48:792-798
4. Khashab M, Chalasani N 2007 Use of insulin sensitizers in NASH. Endocrinol Metab Clin North Am 36:1067-1087
5. Kotronen A, Yki-Järvinen H 2008 Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27-38
6. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, Connolly V, King H 2005 The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28:2130-2135
7. Unger RH 2003 Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144:5159-5165
8. van Herpen NA, Schrauwen-Hinderling VB 2008 Lipid accumulation in nonadipose tissue and lipotoxicity. Physiol Behav 94:231-241
9. Jiang J, Torok N 2008 Nonalcoholic steatohepatitis and the metabolic syndrome. Metab Syndr Relat Disord 6:1-7
10. Margolis RN, Taylor SI, Seminara D, Hubbard AL 1988 Identification of pp120, an endogenous substrate for the hepatocyte insulin receptor tyrosine kinase, as an integral membrane glycoprotein of the bile canalicular domain. Proc Natl Acad Sci USA 85:7256-7259
11. Najjar SM, Choice CV, Soni P, Whitman CM, Poy MN 1998 Effect of pp 120 on receptor-mediated insulin endocytosis is regulated by the juxtamembrane domain of the insulin receptor. J Biol Chem 273:12923-12928
12. McCuaig K, Rosenberg M, Nédellec P, Turbide C, Beauchemin N 1993 Expression of the Bgp gene and characterization of mouse colon biliary glycoprotein isoforms. Gene 127:173-183
13. Nédellec P, Turbide C, Beauchemin N 1995 Characterization and transcriptional activity of the mouse biliary glycoprotein 1 gene, a carcinoembryonic antigen-related gene. Eur J Biochem 231:104-114
14. Formisano P, Najjar SM, Gross CN, Philippe N, Oriente F, Kern-Buell CL, Accili D, Gorden P 1995 Receptor-mediated internalization of insulin. J Biol Chem 270:24073-24077
15. Choice CV, Howard MJ, Poy MN, Hankin MH, Najjar SM 1998 Insulin stimulates pp120 endocytosis in cells co-expressing insulin receptors. J Biol Chem 273:22194-22200
16. Najjar SM, Philippe N, Suzuki Y, Ignacio GA, Formisano P, Accili D, Taylor SI 1995 Insulin-stimulated phosphorylation of recombinant pp120/HA4, an endogenous substrate of the insulin receptor tyrosine kinase. Biochemistry 34:9341-9349
17. Poy MN, Yang Y, Rezaei K, Fernström MA, Lee AD, Kido Y, Erickson SK, Najjar SM 2002 CEACAM1 regulates insulin clearance in liver. Nat Genet 30:270-276
18. Park SY, Cho YR, Kim HJ, Hong EG, Higashimori T, Lee SJ, Goldberg IJ, Shulman GI, Najjar SM, Kim JK 2006 Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. Am J Physiol Endocrinol Metab 291:E517-E524
19. Dai T, Abou-Rjaily GA, Al-Share QY, Yang Y, Fernström MA, DeAngelis AM, Lee AD, Sweetman L, Amato A, Pasquali M, Lopaschuk GD, Erickson SK, Najjar SM 2004 Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. J Biol Chem 279:45155-45161
20. Beauchemin N, Kunath T, Robitaille J, Chow B, Turbide C, Daniels E, Veillette A 1997 Association of biliary glycoprotein with protein tyrosine phosphatase SHP-1 in malignant colon epithelial cells. Oncogene 14:783-790
21. Dubois MJ, Bergeron S, Kim HJ, Dombrowski L, Perreault M, Fournès B, Faure R, Olivier M, Beauchemin N, Schulman GI, Siminovitch K, Kim JK, Marette A 2006 The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med 12:549-556
22. Leung N, Turbide C, Olson M, Marcus V, Jothy S, Beauchemin N 2006 Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) contributes to progression of colon tumors. Oncogene 25:5527-5536
23. Ayala JE, Bracy DP, McGuinness OP, Wasserman DH 2006 Considerations in the design of hyperinsulinemic-euglycemic clamps in the conscious mouse. Diabetes 55:390-397
24. da Luz PL, Favarato D, Faria-Neto Jr JR, Lemos P, Chagas AC 2008 High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics 63:427-432
25. Khan SR, Ayub N, Nawab S, Shamsi TS 2008 Triglyceride profile in dyslipidaemia of type 2 diabetes mellitus. J Coll Physicians Surg Pak 18:270-273
26. Quijada Z, Paoli M, Zerpa Y, Camacho N, Cichetti R, Villarroel V, Arata-Bellabarba G, Lanes R 2008 The triglyceride/HDL-cholesterol ratio as a marker of cardiovascular risk in obese children; association with traditional and emergent risk factors. Pediatr Diabetes 9:464-471
27. Tirosh A, Shai I, Bitzur R, Kochba I, Tekes-Manova D, Israeli E, Shochat T, Rudich A 2008 Changes in triglyceride levels over time and risk of type 2 diabetes in young men. Diabetes Care 31:2032-2037
28. Polonsky KS, Pugh W, Jaspan JB, Cohen DM, Karrison T, Tager HS, Rubenstein AH 1984 C-peptide and insulin secretion. Relationship between peripheral concentrations of C-peptide and insulin and their secretion rates in the dog. J Clin Invest 74:1821-1829
29. DeAngelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Lee SJ, Hong EG, Jung DY, Assmann A, Kulkarni RN, Kim JK, Najjar SM 2008 Carcinoembryonic antigen-related cell adhesion molecule 1: a link between insulin and lipid metabolism. Diabetes 57:2296-2303
30. Taniguchi M, Ueki K, Kahn R 2005 Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J Clin Invest 115:718-727
31. Park SY, Cho YR, Kim HJ, Hong EG, Higashimori T, Lee SJ, Goldberg IJ, Shulman GI, Najjar SM, Kim JK 2006 Mechanism of glucose intolerance in mice with dominant-negative mutation of CEACAM1. Am J Physiol Endocrinol Metab 291:E517-E524
32. Najjar SM, Yang Y, Dai T, Fernström MA, Lee SJ, DeAngelis AM, Rjaily GA, Al-Share QY, Dai T, Miller TA, Ratnam S, Ruch RJ, Smith S, Lin SH, Beauchemin N, Oyarce AM 2005 Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metab 2:43-53
33. Lamarche B, Rashid S, Lewis GF 1999 HDL metabolism in hypertriglyceridemic states: an overview. Clin Chim Acta 286:145-161
34. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, Lewis GF 1999 Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest 103:1191-1199
35. Najjar SM 2002 Regulation of insulin action by CEACAM1. Trends Endocrinol Metab 13:240-245
36. Greenfield JR, Campbell LV 2004 Insulin resistance and obesity. Clin Dermatol 22:289-295
37. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H 2005 The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J Clin Endocrinol Metab 90:5698-5703
38. Cali AM, De Oliveira AM, Taksali S, Shaw M, Savoye M, Pierpont B, Caprio S 2008 Impact of the severity of fatty liver on the risk of prediabetes in obese adolescents. Diabetes 57:A10-A11
39. Donthamsetty S, Bhave VS, Mitra MS, Latendresse JR, Mehendale HM 2008 Nonalcoholic steatohepatitic (NASH) mice are protected from higher hepatotoxicity of acetaminophen upon induction of PPARα with clofibrate. Toxicol Appl Pharmacol 230:327-337
40. Stefano JT, de Oliveira CP, Corrêa-Giannella ML, de Lima VM, de Sá SV, de Oliveira EP, de Mello ES, Giannella-Neto D, Alves VA, Carrilho FJ 2007 Nonalcoholic steatohepatitis (NASH) in ob/ob mice treated with yo jyo hen shi ko (YHK): effects on peroxisome proliferator-activated receptors (PPARs) and microsomal triglyceride transfer protein (MTP). Dig Dis Sci 52:3448-3454
41. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, Kerksiek A, van Kruchten R, Maeda N, Staels B, van Bilsen M, Shiri-Sverdlov R, Hofker MH 2008 Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis. Hepatology 48:474-486
42. Matsuzawa N, Takamura T, Kurita S, Misu H, Ota T, Ando H, Yokoyama M, Honda M, Zen Y, Nakanuma Y, Miyamoto K, Kaneko S 2007 Lipid-induced oxidative stress causes steatohepatitis in mice fed an atherogenic diet. Hepatology 46:1392-1403
43. Illouz F, Roulier V, Rod A, Gallois Y, Pellé CP, Aubé C, Rohmer V, Ritz P, Ducluzeau PH 2008 Distribution of adipose tissue: quantification and relationship with hepatic steatosis and vascular profiles of type 2 diabetic patients with metabolic syndrome. Diabetes Metab 34:68-74
44. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Cornér A, Bergholm R, Yki-Järvinen H 2008 Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31:165-169
45. Turner N, Bruce CR, Beale SM, Hoehn KL, So T, Rolph MS, Cooney GJ 2007 Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 56:2085-2092
46. Casaschi A, Maiyoh GK, Adeli K, Theriault AG 2005 Increased diacylglycerol acyltransferase activity is associated with triglyceride accumulation in tissues of diet-induced insulin-resistant hyperlipidemic hamsters. Metabolism 54:403-409
47. Sperling MA, Fan Y, Menon RK, Cohen P, Hwang D, Clemens T, Kopchik J, Le Roith D, Trucco M 2008 Liver-specific deletion of the growth hormone receptor induces insulin resistance, diabetic glucose tolerance, dyslipidemia and hepatic steatosis, without affecting growth. Diabetes 57:A11
48. Taylor R 2008 Pathogenesis of type 2 diabetes: tracing the reverse route from cure to cause. Diabetologia 51:1781-1789
49. Larter CZ, Yeh MM 2008 Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 23:1635-1648
50. Larter CZ, Farrell GC 2006 Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat? J Hepatol 44:253-261
51. Scheja L, Toedter K, Mohr R, Niederfellner G, Michael MD, Meissner A, Schoettler A, Pospisil H, Beisiegel U, Heeren J 2008 Liver TAG transiently decreases while PL n-3 and n-6 fatty acids are persistently elevated in insulin resistant mice. Lipids 43:1039-1051
52. Matsuzaka T, Shimano H, Yahagi N, Kato T, Atsumi A, Yamamoto T, Inoue N, Ishikawa M, Okada S, Ishigaki N, Iwasaki H, Iwasaki Y, Karasawa T, Kumadaki S, Matsui T, Sekiya M, Ohashi K, Hasty AH, Nakagawa Y, Takahashi A, Suzuki H, Yatoh S, Sone H, Toyoshima H, Osuga J, Yamada N 2007 Crucial role of a long-chain fatty acid elongase, Elovl6, in obesity-induced insulin resistance. Nat Med 13:1193-1202
53. Flowers MT, Ntambi JM 2008 Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr Opin Lipidol 19:248-256
54. Flowers MT, Keller MP, Choi Y, Lan H, Kendziorski C, Ntambi JM, Attie AD 2008 Liver gene expression analysis reveals endoplasmic reticulum stress and metabolic dysfunction in SCD1-deficient mice fed a very low-fat diet. Physiol Genomics 33:361-372
55. Minehira K, Young SG, Villanueva CJ, Yetukuri L, Oresic M, Hellerstein MK, Farese Jr RV, Horton JD, Preitner F, Thorens B, Tappy L 2008 Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice. J lipid Res 49:2038-2044
56. Horton JD 2008 Hepatic steatosis in type 2 diabetes - metabolic and hormonal defects. Diabetes 57(Suppl 1):34